Top Page
Polynovo
(Sydney:PNV)
Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)
Polynovo Business Overview & Revenue Model
Polynovo Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 127.26M | 127.24M | 103.19M | 65.24M | 41.44M | 29.16M |
| Gross Profit | 76.45M | 122.05M | 97.71M | 19.33M | 16.23M | 7.83M |
| EBITDA | 11.10M | 10.45M | 4.05M | -2.71M | 658.24K | -3.41M |
| Net Income | 13.21M | 13.21M | 5.26M | -4.92M | -1.19M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 127.41M | 127.41M | 108.72M | 92.62M | 34.97M | 38.34M |
| Cash, Cash Equivalents and Short-Term Investments | 33.59M | 33.59M | 45.96M | 46.90M | 6.15M | 7.74M |
| Total Debt | 17.14M | 17.14M | 15.38M | 16.04M | 10.99M | 10.00M |
| Total Liabilities | 44.15M | 44.15M | 36.60M | 27.24M | 17.26M | 15.99M |
| Stockholders Equity | 83.26M | 83.26M | 72.12M | 65.38M | 17.72M | 22.35M |
Cash Flow | ||||||
| Free Cash Flow | -10.68M | -10.78M | 786.00K | -7.46M | -2.55M | -3.82M |
| Operating Cash Flow | 3.25M | 3.15M | 3.68M | -5.93M | -2.06M | -248.74K |
| Investing Cash Flow | -13.93M | -13.22M | -1.49M | -1.53M | 5.86M | -3.57M |
| Financing Cash Flow | -2.39M | -2.39M | -3.17M | 48.06M | -5.39M | -70.37K |
Polynovo Technical Analysis
Polynovo Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$274.30M | -78.71 | -4.06% | ― | 20.36% | 64.81% | |
58 Neutral | $842.83M | 62.57 | 16.49% | ― | 23.31% | 151.32% | |
55 Neutral | $178.91M | -51.25 | -7.26% | ― | 21.65% | 81.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
41 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
Polynovo Corporate Events
At the Annual General Meeting held on October 28, 2025, PolyNovo Limited successfully passed several key resolutions, including the re-election of directors Leon Hoare and David Williams, and the election of Robert Douglas as a director. The adoption of the remuneration report and approval of non-executive directors’ fees were also carried. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo has reported a strong financial year with significant growth in commercial sales and regulatory clearances, expanding its market reach to 46 countries. The company is poised for further growth with the upcoming commercialization of new products and anticipated pricing reforms, supported by a robust cash position and strategic leadership changes.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has announced the resignation of its Chairman, David Williams, with Leon Hoare stepping in as the new Chair. This leadership change aligns with the company’s board succession plans and governance review, ensuring a smooth transition without disrupting operations or strategic direction. Under Williams’ leadership, PolyNovo transformed into a global medical technology company, achieving record sales growth and expanding its presence to 46 countries. The company remains committed to its business strategy and growth plans.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited announced the appointment of Robert Douglas as a director, effective October 14, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team and enhance its market position in the medical technology sector. The announcement does not indicate any current securities or contract interests held by the new director, suggesting a fresh start in his role.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has announced the appointment of Mr. Robert Douglas as a new Non-Executive Director, with a resolution for his election to be proposed at the upcoming Annual General Meeting. Mr. Douglas brings extensive experience from his previous role as Global Chief Operating Officer at ResMed, and his expertise is expected to enhance the board’s skillset and governance, benefiting the company and its stakeholders.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has appointed Bruce Peatey as the new CEO, effective December 1, 2025. With extensive experience in healthcare, medical devices, and biotechnology, Peatey brings valuable skills in managing quality and regulatory functions, strategic business development, and market expansion. His leadership is expected to drive PolyNovo’s growth into new markets and enhance its international presence, particularly in the outpatient sector. The company anticipates that Peatey’s expertise and established relationships in the industry will inform its strategic approach to distribution in the US and key international markets.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has appointed Mr. Robert Douglas as a Non-Executive Director to its Board. Mr. Douglas brings over 35 years of experience in medical device technology and public company governance, with a strong background in digital health and international business expansion. His previous roles at ResMed and current position with Globus Medical highlight his expertise in patient data management and cloud technology, which are expected to benefit PolyNovo’s strategic growth and innovation efforts.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced a change in the director’s interest, with David Williams acquiring an additional 55,000 ordinary shares through Moggs Creek Pty Ltd, a related entity. This acquisition, valued at $87,997.91, increases his total holdings to 21,655,000 shares, reflecting confidence in the company’s market position and potential growth, which may positively impact stakeholders’ perception.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Ltd has announced that Citigroup Global Markets Australia Pty Limited and its related entities have ceased to be substantial holders in the company as of September 16, 2025. This change in substantial holding reflects a decrease in Citigroup’s relevant interest in Polynovo’s voting securities, which may impact the company’s shareholder structure and market perception.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has announced a change in the director’s interest, with Dr. Robyn Elliott acquiring 20,000 ordinary fully paid shares through an on-market trade. This acquisition increases Dr. Elliott’s total holdings to 94,789 shares, reflecting a vote of confidence in the company’s prospects and potentially impacting investor perception positively.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced a change in the director’s interest, with David Williams acquiring an additional 50,030 ordinary shares through an on-market trade, increasing his total holdings to 21,600,000 shares. This acquisition, valued at $75,045, reflects continued confidence in the company’s prospects and could potentially influence investor perception positively.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced a change in the director’s interest in securities, specifically regarding David Williams, a director and controller of Moggs Creek Pty Ltd. The change involved the acquisition of 61,335 ordinary shares by Moggs Creek Pty Ltd, a related entity of Mr. Williams, through an on-market trade, increasing his total holdings to 21,549,970 shares. This transaction, valued at $85,975.35, reflects an active engagement in the company’s stock by its director, potentially indicating confidence in the company’s future performance.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited announced promising results from a randomized controlled trial evaluating its NovoSorb BTM product for post-surgical diabetes-related foot wounds. The study demonstrated that NovoSorb BTM significantly accelerates healing of large wounds compared to standard care, reducing the time to complete healing by over four months. This positions NovoSorb BTM as a valuable option in the limited treatment landscape for diabetic foot wounds, potentially influencing outpatient adoption and treatment practices, especially in the U.S. if CMS pricing changes in 2026.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has requested a trading halt on its securities pending the release of an announcement related to a clinical trial. The trial investigates the effectiveness of NovoSorb BTM combined with negative pressure wound therapy compared to standard care in treating neuroischemic diabetic wounds. This announcement could have significant implications for PolyNovo’s market positioning and stakeholder interests, as it pertains to the potential efficacy of their product in a critical area of wound care.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited announced a change in the director’s interest notice, indicating that Director David Williams has acquired an additional 31,000 ordinary shares through Moggs Creek Pty Ltd, a related entity. This acquisition, completed via an on-market trade, reflects a continued investment in the company, potentially signaling confidence in Polynovo’s strategic direction and market position.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited announced a change in the director’s interest, with Mr. Leon Hoare acquiring an additional 20,000 ordinary fully paid shares through his personal super account. This transaction, executed via an on-market trade, reflects a continued commitment by the director to the company’s growth and stability, potentially signaling confidence in PolyNovo’s future prospects to stakeholders.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced a change in the director’s interest notice involving David Williams, a director and controller of Moggs Creek Pty Ltd. The company operates in the medical technology industry, focusing on the development and commercialization of innovative wound care solutions. The announcement details that Moggs Creek Pty Ltd, a related entity of Mr. Williams, acquired 37,000 ordinary shares at a total value of $51,980.04 through an on-market trade. This acquisition increases the total number of shares held by Mr. Williams to 21,457,635. The transaction did not occur during a closed period, indicating compliance with trading regulations.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo’s 2025 Annual Report highlights its strategic focus on expanding global reach and product offerings, particularly with NovoSorb MTX. The company is enhancing its market position by scaling operations and driving growth through innovation, which is expected to benefit stakeholders by improving patient outcomes and increasing market penetration.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced that UBS Group AG and its related bodies corporate have ceased to be substantial shareholders as of August 29, 2025. This change may impact Polynovo’s shareholder composition and could influence market perceptions or investor relations, although specific implications for stakeholders were not detailed in the release.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.30 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited is poised to benefit from proposed changes to U.S. Medicare reimbursement for outpatient wound care, which aim to create a more value-oriented market by implementing a flat reimbursement rate. This change could enhance the competitiveness of PolyNovo’s cost-effective products, sustain their profit margins, and open significant growth opportunities in the outpatient sector, particularly as physicians focus more on clinical outcomes.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.30 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has requested a trading halt on its securities pending the release of an announcement. This move is in response to press speculation about a potential positive change in U.S. reimbursement for outpatient wound care, which could significantly impact the company’s operations and market positioning.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.30 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo has released a webcast recording of its FY25 results presentation for shareholders and interested parties who could not attend the live session. This announcement, authorized by the company’s secretary, includes updates from the CEO, financial results, chairman’s commentary, and a Q&A session, reflecting the company’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo has conducted a comprehensive review of its corporate governance practices in alignment with the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes ethical behavior, integrity, and compliance with the law to uphold its reputation and stakeholder trust. The governance framework includes a structured Board and committees, with a focus on diversity, performance evaluation, and ethical conduct, which are crucial for its operational integrity and industry positioning.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This announcement underscores PolyNovo’s dedication to maintaining robust governance practices, which is crucial for sustaining investor confidence and aligning with industry standards.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo’s recent announcement highlights the capabilities of its NovoSorb matrix in promoting regenerative healing by organizing large wounds into smaller ones, which the body can heal more effectively. This advancement is expected to enhance the company’s market position in the regenerative medicine sector, potentially benefiting stakeholders by improving patient outcomes and expanding market reach.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited reported a significant increase in its financial performance for FY25, with group sales reaching A$118.6 million, marking a 28.9% increase from the previous year. The company achieved a net profit after tax of A$13.2 million, a 151.2% rise from the prior year. Key achievements include the successful U.S. launch of NovoSorb MTX, strong sales growth in various international markets, and the registration of NovoSorb products in multiple countries. These developments enhance PolyNovo’s market positioning and indicate a positive trajectory for future growth.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited is a Melbourne-based medical technology company specializing in innovative solutions for acute complex wounds, leveraging its proprietary NovoSorb technology to redefine healing across multiple wound etiologies. In its latest earnings report, PolyNovo Limited announced a significant increase in its financial performance for the fiscal year 2025, with group sales reaching A$118.6 million, marking a 28.9% increase from the previous year. The company’s net profit after tax also saw a remarkable rise of 151.2% to A$13.2 million. Key highlights include strong sales growth in the U.S. and other international markets, successful product launches, and strategic expansions in research and manufacturing capabilities. The company’s NovoSorb MTX and BTM products have gained new regulatory approvals, enhancing their market presence and application scope. Looking ahead, PolyNovo’s management remains optimistic about continued growth, focusing on expanding its product portfolio and market reach while completing its new manufacturing facility and advancing clinical trials.
PolyNovo announced a live-streamed presentation of its FY25 results, scheduled for 25 August. The presentation will provide insights into the company’s performance and future plans, potentially impacting its operations and market positioning. Shareholders and analysts are invited to participate and ask questions, highlighting the company’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced that UBS Group AG and its related bodies corporate have ceased to be substantial shareholders as of August 7, 2025. This change in shareholding may influence Polynovo’s market dynamics and investor relations, as substantial shareholders often play a significant role in a company’s strategic decisions.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.